MRCP

RS Oncology Announces Positive Data from a Phase 1 Clinical Trial of RSO-021, a First-in-Class Therapeutic for Malignant Pleural Mesothelioma

Retrieved on: 
Lunedì, Giugno 3, 2024
Oncology, Health, Infectious Diseases, Hospitals, Radiology, Pharmaceutical, Biotechnology, ASCO, Cancer, Mesothelioma, Lung, Multimedia, Prognosis, Patient, MPE, Peritoneum, Annual general meeting, Malignant pleural effusion, Metastasis, Trial of the century, Safety, Society, FRCP, Pericardium, Hearing, Pleural cavity, Doctor of Philosophy, MPM, Quality of life, MD–PhD, Survival, MRCP, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240603559175/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240603559175/en/
    Professor Dean Fennell, principal investigator, presents results from the Phase 1 MITOPE clinical study of a first-in-human, and potential first-in-class therapeutic, RSO-021.
  • (Photo: Business Wire)
    The Phase 1 data was presented by Professor Dean Fennell, MRCP, FRCP (MD/PhD) on behalf of all the MITOPE investigators at an oral presentation session.
  • In the 15 recruited patients safety data demonstrated weekly treatment of RSO-021 was well tolerated at 90 mg.
  • The safety and efficacy observed in the Phase 1 trial is supported by strong pre-clinical rationale” said Brian Cunniff, PhD, Chief Science Officer for RS Oncology.

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

Retrieved on: 
Sabato, Giugno 1, 2024
Aes, Bronchospasm, Comment, Patient, Annual general meeting, McCormick Place, Sant Joan, DCH, Cancer, Abdominal pain, Society, Therapy, Radioimmunotherapy, Bone marrow, Disease, Granulocyte-macrophage colony-stimulating factor, Pain, Hypotension, MBBS, Poster, MSK, MRCP, Pharmaceutical industry

The results are summarized in poster presentations scheduled to be presented today, June 1, 2024, at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, IL.

Key Points: 
  • The results are summarized in poster presentations scheduled to be presented today, June 1, 2024, at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, IL.
  • The Trial 201 prespecified interim analysis achieved a 50% overall response rate (“ORR”) in 26 out of 52 patients.
  • Nearly a quarter of patients achieved their first complete response (“CR”) or partial response (“PR”) after three or more cycles of naxitamab therapy.
  • These results support the rationale for extended naxitamab therapy in patients who do not achieve a CR or PR at first assessment.

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

Retrieved on: 
Sabato, Giugno 1, 2024
Lanthanum, Comment, DOTA, GD2, Patient, Annual general meeting, McCormick Place, Cancer, DCH, Society, Therapy, Radioimmunotherapy, Lutetium, Diagnosis, MBBS, MSK, MRCP, Medical device

In this analysis, GD2-SADA showed tight binding to cell lines expressing GD2, a glycolipid implicated in the malignant transformation of multiple solid tumors.

Key Points: 
  • In this analysis, GD2-SADA showed tight binding to cell lines expressing GD2, a glycolipid implicated in the malignant transformation of multiple solid tumors.
  • Previous studies have shown that the unbound GD2-SADA protein disassembles over time, facilitating clearance by the kidneys.
  • The analysis further demonstrated high-affinity binding of GD2-SADA to DOTA complexes chelated with lutetium and lanthanum, among other lanthanide metals.
  • Researchers at MSK, including Dr. Nai-Kong Cheung, developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs.

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo

Retrieved on: 
Lunedì, Giugno 3, 2024
General Health, Neurology, Health, Pharmaceutical, Clinical Trials, Cerebrospinal fluid, ESS, Breakthrough therapy, Patient, Neuron, Narcolepsy, Sleep paralysis, Data, Patient satisfaction, Safety, Hypnagogia, Sleep Research Society, Sleep, Hepatotoxicity, Somnolence, Epworth Sleepiness Scale, WCR, Head, EDS, DSM-IV codes, Quality of life, American Academy, Food, MWT, LTE, OX2R, Brain, FDA, Insomnia, Cataplexy, MRCP, Pharmaceutical industry

People with NT1 suffer from excessive daytime sleepiness (EDS), cataplexy (sudden loss of muscle tone), disrupted nighttime sleep, hypnagogic and hypnopompic hallucinations and sleep paralysis.

Key Points: 
  • People with NT1 suffer from excessive daytime sleepiness (EDS), cataplexy (sudden loss of muscle tone), disrupted nighttime sleep, hypnagogic and hypnopompic hallucinations and sleep paralysis.
  • TAK-861 is designed to address the orexin deficiency in NT1 by selectively stimulating the orexin receptor 2.
  • The trial also included additional exploratory endpoints that showed meaningful improvements in narcolepsy symptoms and functioning according to most participants.
  • No cases of hepatotoxicity or visual disturbances were reported in the Phase 2b trial or in the ongoing LTE study.

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

Retrieved on: 
Mercoledì, Maggio 22, 2024
University of Hong Kong, Doctor of Philosophy, Doctor of Science, EASL, Congress, University, Therapy, FRCP, SAN, Division, Abstract, MBBS, MRCP, Hepatology

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstracts have been accepted for poster presentations, including two Top abstracts, at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstracts have been accepted for poster presentations, including two Top abstracts, at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.
  • The abstracts released today can be found on the EASL website at www.easlcongress.eu .
  • Details from the abstracts released today are as follows:
    Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
    Presenter: Kosh Agarwal, MBBS, MRCP (UK), MD, FRCP (Ed), FRCP (London), Consultant Hepatologist and Transplant Physician, Institute of liver Studies, King’s College Hospital NHS Foundation Trust
    Abstracts identified as “Top” were selected as among the best in their category.
  • These posters will be displayed during the four days of the congress.

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease

Retrieved on: 
Lunedì, Maggio 13, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Managed Care, Health, Clinical Trials, Patient, Plaque, Amyloid beta, Safety, Form, Form 6-K, Head, Brain, AC, Hart–Scott–Rodino Antitrust Improvements Act, MRCP, Down syndrome, Multimedia, ABATE, Pharmaceutical industry

Takeda ( TSE:4502/NYSE:TAK ) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer’s disease.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer’s disease.
  • By inducing plaque clearance and efficiently inhibiting plaque formation in the brain, ACI-24.060 has the potential to delay or slow Alzheimer’s disease progression.
  • “At Takeda, we are committed to tackling some of society’s most debilitating illnesses, including Alzheimer’s disease.
  • Further details related to the agreement are available in the Form 6-K filed today by AC Immune with the U.S. Securities and Exchange Commission (SEC).

ACELYRIN, INC. Announces Leadership Transition

Retrieved on: 
Giovedì, Maggio 9, 2024
Corporation, Sale, Zymergen, Graves' ophthalmopathy, Immunotherapy, History, Administration, MRCP, Corporate development, IPO, Patient, Synthetic biology, LOS, SLRN, FRCP, Renewable energy, INC, Knowledge, Aviation, Management

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that ACELYRIN’s founder Shao-Lee Lin, M.D., Ph.D. has stepped down as Chief Executive Officer and that Mina Kim, chief legal and administrative officer at ACELYRIN, has been appointed Chief Executive Officer and to the company’s Board of Directors (the “Board”).

Key Points: 
  • Ms. Kim brings more than 20 years of operational and leadership experience across a range of industries including synthetic biology, immunotherapy, renewable energy, and aviation.
  • Ms. Kim played a pivotal role in ACELYRIN’s initial public offering and has served as ACELYRIN’s Chief Legal and Administrative Officer since November 2022.
  • “With encouraging data across our pipeline, we are continuing to advance our core mission of making a meaningful difference for patients.
  • The company will file the related quarterly report on Form 10-Q no later than May 14, 2024.

ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones

Retrieved on: 
Giovedì, Maggio 9, 2024
Psoriatic arthritis, Hyperglycemia, Graves' ophthalmopathy, Abscess, Huber loss, Risk, QW, Hidradenitis suppurativa, Conference, Webcast, Suicidal ideation, Development, MRCP, Disease, Patient, Fungus, LOS, SLRN, Diplopia, FRCP, IL-17A, POC, CAS, Quality of life, Exophthalmos, Behavior, Infection, Pharmaceutical industry

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today provided an update on various corporate milestones.

Key Points: 
  • This Phase 2b/3 trial, designed to be the first of two registrational trials in TED, is planned to be initiated in the second half of 2024.
  • Izokibep in Uveitis (UV): ACELYRIN expects to complete enrollment in the ongoing Phase 2b/3 trial this month and top line data are anticipated by year-end 2024.
  • ACELYRIN expects to report cash, cash equivalents, and short-term marketable securities of $678.5 million at March 31, 2024.
  • Gil Labrucherie, who serves as ACELYRIN’s Chief Financial Officer, has also been named Chief Business Officer in addition to Chief Financial Officer.

Surrey Cardiovascular Clinic and Caristo Diagnostics Launch Employee Heart Wellness and Disease Prevention Program for UK Employers

Retrieved on: 
Martedì, Aprile 23, 2024
University, Cancer, NHS, Risk, Coronary artery disease, CDC, Heart, VCL, MD, Mace, Partnership, Research, MRCP, Atherosclerosis, Patient, Splenic infarction, Death, Chest pain, Artery, Plaque, Imaging, CCTA

OXFORD, England and SURREY, England , April 23, 2024 /PRNewswire/ -- Surrey Cardiovascular Clinic (SCVC), Southern England's leading centre of excellence for the prevention and treatment of cardiovascular and cancer issues, has partnered with Imaging provider VCL SURREY and Caristo Diagnostics, a leading cardiac disease diagnostics company, to offer the novel CaRi-Heart® AI technology to predict patients' risk of developing potentially fatal coronary artery disease.

Key Points: 
  • SCVC will provide the CaRi-Heart AI-based cardiac assessment as a central part of the organisations 's employee wellness initiative for UK employers.
  • In combination with the programme's other tests, Cari-Heart provides the ability to predict future heart attacks and atherosclerosis many years before symptoms occur.
  • We are pleased to announce our partnership with Surrey Cardiovascular Clinic and their imaging partner VCL Surrey to enhance accessibility to CaRi-Heart technology for employees throughout the UK," said Frank Cheng, CEO of Caristo Diagnostics.
  • The CaRi-Heart technology is currently in clinical use in various NHS and private hospitals in the UK, as well as within the EU and Australia.

Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award

Retrieved on: 
Domenica, Aprile 14, 2024
Inflammation, Congress, ECP, Blood, Cell death, EIA, Research, MRCP, Science, Medicine, Haematopoietic system, EBMT, Teaching hospital, Immunomodulation, Knowledge, Monocyte, Pharmaceutical industry

DUBLIN, April 14, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmacy company, today announced that submissions for its 2024 Extracorporeal Immunomodulation Award (EIA) will open on 13 April 2024 during the 50th Annual Meeting of the European Bone Marrow Transplant Meeting (EBMT), Europe's largest annual congress in blood and bone marrow transplantation and cellular therapies. In recognition of 30 years since clinicians first used ECP to successfully treat chronic GvHD,1 Mallinckrodt, provider of immunomodulatory therapy via Extracorporeal Photopheresis (ECP) and manufacturer of the world's only fully integrated, validated, ECP system, is pleased to mark this important milestone by this year dedicating the award to the study of ECP for cGvHD.

Key Points: 
  • Host Disease (cGvHD), this year's grant is to be dedicated to research in cGvHD --
    DUBLIN, April 14, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmacy company, today announced that submissions for its 2024 Extracorporeal Immunomodulation Award (EIA) will open on 13 April 2024 during the 50th Annual Meeting of the European Bone Marrow Transplant Meeting (EBMT), Europe's largest annual congress in blood and bone marrow transplantation and cellular therapies.
  • "Mallinckrodt has pioneered ECP immunomodulation through its THERAKOSTM CELLEXTM Photopheresis System and is pleased to support continued research that further contributes to this field of medicine," said Peter Richardson, MRCP (UK), Executive Vice President & Chief Scientific Officer.
  • Entries to the 2024 EIA Award will close on 1 September 2024.
  • This event will be presented by the GvHD Hub, and supported through an unrestricted educational grant from Therakos, Mallinckrodt.